Revelation Biosciences Bolsters Kidney Injury Board

Revelation Biosciences Inc. (NASDAQ: REVB) has announced an expansion of its Acute Kidney Injury (AKI) Advisory Board, bringing on two new experts to guide the clinical development of its lead asset, REV-002. The additions of Dr. Mitchell H. Rosner and Dr. Chirag R. Parikh aim to strengthen the company's strategic approach to addressing this significant medical condition. This move underscores the firm's focus on advancing therapies for the prevention and treatment of AKI, reflecting its commitment to addressing unmet medical needs.

Key Appointments Enhance AKI Expertise

The newly expanded Advisory Board now includes Dr. Mitchell H. Rosner, MD, MACP, and Dr. Chirag R. Parikh, MD, PhD, FASN. They join existing distinguished members Dr. Stuart L. Goldstein, MD, FASN, and Dr. Lakhmir S. Chawla, MD, FASN. These appointments are intended to provide specialized guidance for the upcoming clinical trials and strategic direction for the REV-002 program.

Dr. Rosner, a Professor of Medicine and Chair of the Department of Medicine at the University of Virginia, is recognized internationally for his work in kidney disease. His research primarily focuses on the understanding and treatment of both acute and chronic kidney injuries. He previously served as Past President of the American Society of Nephrology, demonstrating his leadership in the field.

Dr. Parikh holds the position of Director of the Division of Nephrology at Johns Hopkins University School of Medicine. He is a leading authority in the AKI field, known for his contributions to biomarker discovery and clinical trial design. Dr. Parikh has also been instrumental in developing novel diagnostic and prognostic tools for AKI, further solidifying his expertise.

"We are delighted to welcome Dr. Rosner and Dr. Parikh to our Acute Kidney Injury Advisory Board. Their exceptional experience and profound insights in nephrology and AKI research will be invaluable as we advance REV-002 through clinical development. The expansion of our advisory board underscores our commitment to addressing the urgent unmet medical needs in AKI and strengthening our clinical strategy."

Advancing REV-002 for Acute Kidney Injury

REV-002, a recombinant humanized tissue inhibitor of metalloproteinase 2 (TIMP-2), is Revelation Biosciences' primary clinical asset for AKI. The company recently concluded a Phase 1 clinical trial for REV-002, which confirmed its safety and tolerability profile. This successful completion marks a crucial step forward in its development and preparation for advanced studies.

The company anticipates initiating a Phase 2 clinical trial for REV-002 in patients at high risk for AKI during the third quarter of 2024. This next phase will further evaluate the drug's efficacy and safety in a larger patient population, moving closer to potential therapeutic solutions. Revelation Biosciences aims to address the significant challenges associated with AKI through this therapeutic candidate's progression.

Acute Kidney Injury is a serious medical condition characterized by a sudden and often severe decline in kidney function. This condition can lead to kidney failure, increased mortality rates, and extended hospital stays for affected individuals. Current therapeutic options specifically approved for AKI prevention and treatment remain limited, highlighting a substantial need for new treatments and improved patient outcomes.

The expansion of Revelation Biosciences' AKI Advisory Board signals the company's intensified focus on its lead clinical program, REV-002. With enhanced expert guidance, the firm is preparing for its Phase 2 clinical trial, aiming to provide a much-needed therapeutic option for patients at risk of Acute Kidney Injury. This strategic move aligns with Revelation Biosciences' goal of addressing critical unmet medical needs in the life sciences sector, potentially improving patient outcomes for a serious condition.